GoodRx (GDRX)
(Delayed Data from NSDQ)
$7.19 USD
+0.11 (1.55%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $7.24 +0.05 (0.70%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
Income Statements
Fiscal Year end for GoodRx Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 750 | 767 | 745 | 551 | 388 |
Cost Of Goods | 67 | 65 | 47 | 30 | 14 |
Gross Profit | 683 | 701 | 699 | 521 | 374 |
Selling & Adminstrative & Depr. & Amort Expenses | 710 | 700 | 685 | 797 | 235 |
Income After Depreciation & Amortization | -27 | 2 | 13 | -276 | 140 |
Non-Operating Income | 28 | 9 | 0 | 0 | -7 |
Interest Expense | 57 | 34 | 24 | 28 | 50 |
Pretax Income | -56 | -23 | -10 | -303 | 83 |
Income Taxes | -47 | 10 | 15 | -10 | 17 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -9 | -33 | -25 | -294 | 66 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -9 | -33 | -25 | -294 | 66 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 84 | 59 | 51 | -254 | 157 |
Depreciation & Amortization (Cash Flow) | 111 | 58 | 38 | 22 | 17 |
Income After Depreciation & Amortization | -27 | 2 | 13 | -276 | 140 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 410.32 | 412.86 | 409.98 | 274.70 | NA |
Diluted EPS Before Non-Recurring Items | 0.13 | 0.07 | 0.02 | -0.96 | NA |
Diluted Net EPS (GAAP) | -0.02 | -0.08 | -0.06 | -1.07 | 0.18 |
Fiscal Year end for GoodRx Holdings, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 196.64 | 179.96 | 189.68 | 183.99 |
Cost Of Goods | NA | 15.17 | 18.72 | 16.34 | 16.70 |
Gross Profit | NA | 181.47 | 161.24 | 173.34 | 167.29 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 199.76 | 199.56 | 155.04 | 155.99 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -18.29 | -38.32 | 18.30 | 11.30 |
Non-Operating Income | NA | 8.47 | 6.45 | 7.81 | 5.43 |
Interest Expense | NA | 14.82 | 14.72 | 14.05 | 13.13 |
Pretax Income | NA | -24.64 | -46.60 | 12.07 | 3.60 |
Income Taxes | NA | 1.23 | -8.11 | -46.72 | 6.89 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -25.87 | -38.50 | 58.79 | -3.29 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -25.87 | -38.50 | 58.79 | -3.29 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 403.25 | 413.44 | 414.34 | 412.43 |
Diluted EPS Before Non-Recurring Items | NA | 0.02 | 0.00 | 0.02 | 0.01 |
Diluted Net EPS (GAAP) | NA | -0.06 | -0.09 | 0.14 | -0.01 |